A leading ferroptosis researcher warns that the field may be moving too fast toward clinical translation

A new perspective article argues that despite explosive growth in ferroptosis research, several foundational questions about this iron-dependent form of cell death remain unresolved.

Published in the open-access journal Ferroptosis and Oxidative Stress, the article "Key questions in ferroptosis" by Andreas Linkermann reflects on major conceptual blind spots that may limit the field’s ability to successfully translate ferroptosis research into clinical therapies.

Since ferroptosis was first conceptualized in 2012, the field has expanded rapidly, generating tens of thousands of publications focused on cancer therapy, neurodegeneration, ischemia-reperfusion injury, organ transplantation, and inflammatory disease. Much of this enthusiasm stems from two major therapeutic ideas: inducing ferroptosis to kill cancer cells and inhibiting ferroptosis to protect tissues from injury.

However, the article argues that this rapid expansion has created a "gold rush" atmosphere in which fundamental biological questions risk being overlooked.

The author highlights several unresolved conceptual problems that continue to shape the field.

1. Ferroptosis may not be a classical "pathway"

The article challenges a common assumption in the field: that ferroptosis can be defined by a single molecular pathway.

Instead, ferroptosis is described as iron-catalyzed necrotic cell death that is constantly opposed by multiple protective systems, including GPX4, FSP1, thioredoxin, hydropersulfides, estrogens, and lipid remodeling pathways. These systems collectively determine a cell's  "ferroptotic threshold."

Because different tissues rely on different anti-ferroptotic mechanisms, the author argues that no single regulator can serve as a universal marker of ferroptosis. This raises an important conceptual shift: ferroptosis may be better understood as a biochemical condition of catastrophic lipid peroxidation rather than a linear signaling cascade.

2. There is still no definitive biomarker for ferroptosis

Although lipid peroxidation is widely used as evidence of ferroptosis, the article emphasizes that lipid oxidation occurs in many biological contexts and is not specific to ferroptotic death.

Currently, no tissue marker, serum biomarker, or clinical assay can definitively identify ferroptosis in patients. According to the author, this represents one of the greatest barriers to clinical translation, particularly for evaluating ferroptosis-targeting therapies in human trials.

3. Ferroptosis may suppress adaptive immunity

Unlike many forms of necrotic cell death that stimulate immune activation, ferroptotic cells may actively inhibit adaptive immune responses.

The article discusses evidence showing that oxidized phospholipids released during ferroptosis can impair dendritic cell cross-priming, potentially suppressing T-cell activation. This could explain why ischemic injuries in organs such as the brain, heart, kidney, and liver often show limited adaptive immune infiltration despite severe tissue necrosis.

These findings suggest that ferroptosis may possess a distinct immunological identity compared with other forms of regulated necrosis.

4. Ferroptosis appears partly disconnected from classical cell death networks

The author further argues that ferroptosis remains mechanistically separated from the caspase- and kinase-driven regulatory systems that govern apoptosis, necroptosis, and pyroptosis.

Because iron-driven lipid peroxidation predates multicellular life evolutionarily and is also observed in plants, ferroptosis may represent a more ancient biological process than other regulated cell death programs. How ferroptosis integrates into broader cellular fate networks remains largely unknown.

5. Why does ferroptosis spread between neighboring cells?

One of the most intriguing unresolved observations discussed in the article is "cell-death propagation," in which ferroptotic damage spreads across neighboring cells in wave-like patterns.

This phenomenon is particularly evident in kidney tubules and ischemic injury models but absent in many standard cell-culture systems. Understanding why ferroptosis propagates under some conditions but not others may have major clinical implications for stroke, myocardial infarction, and organ injury.

6. What is the physiological function of ferroptosis?

The article questions whether ferroptosis itself has an adaptive biological purpose or whether evolution instead selected for anti-ferroptotic defense systems.

The author proposes that after oxygen became abundant on Earth, lipid membranes would have been inherently vulnerable to iron-catalyzed destruction. From this perspective, anti-ferroptotic systems may have evolved primarily to protect life from spontaneous membrane oxidation.

Currently, only a few physiological roles for ferroptosis are clearly recognized, including embryonic duct degeneration during development.

7. Can ferroptosis therapies be translated safely into medicine?

Finally, the article stresses that safety concerns remain largely underexplored.

Because ferroptosis-sensitive tissues include kidney tubules, endocrine organs, and embryonic tissues, both ferroptosis inducers and inhibitors may carry significant risks. The author argues that future clinical translation must carefully evaluate on-target toxicities while exploring promising applications in organ preservation, cardiac reperfusion injury, stroke intervention, and post-resuscitation medicine.

Rather than discouraging ferroptosis research, the article calls for a deeper mechanistic understanding of the field before large-scale therapeutic implementation.

The perspective concludes that answering these conceptual questions may be essential for transforming ferroptosis from a rapidly expanding research topic into a clinically actionable biological framework.